Drugs / Metabolically Armed TIL cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07349160 | Jan 2026 → Mar 2027 expected | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 0 | NCT07106814 | Aug 2025 → Aug 2027 expected | cancer | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metabolically Armed TIL cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07349160 ↗ |
| Known as | Meta10-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07307053 ↗ |
| Modality | Cell therapy | “metabolically armed TIL cells” NCT07106814 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT07106814 ↗ |